1
EXHIBIT 11.1
ARONEX PHARMACEUTICALS, INC. AND SUBSIDIARIES
STATEMENT REGARDING COMPUTATION OF PER SHARE EARNINGS
The following reflects the information used in calculating the number of shares
in the computation of net loss per share for each of the periods set forth in
the Statements of Operations.
INCOME
AVERAGE (LOSS)
DAYS SHARES INCOME PER
SHARES OUTSTANDING SHARES X DAYS OUTSTANDING (LOSS) SHARE
NINE MONTHS ENDED SEPTEMBER 30, 1999: 16,379,309 3 49,137,927
16,415,664 50 820,783,200
22,415,664 14 313,819,296
22,463,211 21 471,727,431
22,474,987 1 22,474,987
22,494,671 1 22,494,671
22,495,050 64 1,439,683,200
22,496,505 26 584,909,130
22,555,435 1 22,555,435
22,555,977 8 180,447,816
22,560,179 27 609,124,833
22,697,866 20 453,957,320
22,719,999 6 136,319,994
22,723,765 3 68,171,295
22,723,927 13 294,411,051
22,773,927 5 113,869,635
22,775,753 9 204,981,777
22,788,071 1 22,788,071
273 5,832,657,069 /273 21,365,044 (7,305,000) (0.34)
NINE MONTHS ENDED SEPTEMBER 30, 2000:
22,853,782 21 479,929,422
22,873,782 3 68,621,346
22,876,765 4 91,507,060
22,877,930 12 274,535,160
22,879,230 23 526,222,290
22,888,646 6 137,331,876
22,905,144 14 320,672,016
22,922,078 54 1,237,792,212
25,854,652 44 1,137,604,688
25,890,127 1 25,890,127
25,890,127 74 1,915,869,398
25,890,567 1 25,890,567
25,900,901 5 129,504,505
25,913,022 2 51,826,044
25,918,209 7 181,427,463
25,918,417 2 51,836,834
25,932,005 1 25,932,005
274 6,682,393,013 /274 24,477,630 (12,049,000) (0.49)
QUARTER ENDED SEPTEMBER 30, 1999: 22,555,977 8 180,447,816
22,560,179 27 609,124,833
22,697,866 20 453,957,320
22,719,999 6 136,319,994
22,723,765 3 68,171,295
22,723,927 13 295,411,051
22,723,927 5 113,869,635
22,775,753 9 204,981,777
22,788,071 1 22,788,071
92 2,085,071,792 /92 22,663,824 (5,399,000) (0.24)
QUARTER ENDED SEPTEMBER 30, 2000:
25,890,127 74 1,915,869,398
25,890,567 1 25,890,567
25,900,901 5 129,504,505
25,913,022 2 51,826,044
25,918,209 7 181,427,463
25,918,417 2 51,836,834
25,932,005 1 25,932,005
92 /92 25,894,422 (4,131,000) (0.16)
- 14 -